Journal of the Chinese Medical Association
Volume 69, Issue 12 , Pages 589-590 , December 2006

Methylphenidate (Ritalin)-associated Cataract and Glaucoma

  • Chao-Kung Lu

      Affiliations

    • Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Tung-Mei Kuang

      Affiliations

    • Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Joe Ching-Kuang Chou

      Affiliations

    • Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr Joe Ching-Kuang Chou, Department of Ophthalmology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.

Received 24 October 2005 ,Accepted 31 October 2006.

References 

  1. Rappley MD . Safety issues in the use of methylphenidate: an American perspective . Drug Saf . 1997;7:143–148
  2. Bartlik B , Harmon G . Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma . Arch Gen Psychiatry . 1997;54:188–189
  3. Shahzad S, Suleman MI, Shahab H, Mazour I, Kaur A, Rudzinskiy P, et al. Cataract occurrence with antipsy-chotic drugs . Psychosomatics . 2002;43:354–359
  4. Kimko HC , Cross JT , Abernethy DR . Pharmacokinetics and clinical effectiveness of methylphenidate . Clin Pharmacokinet . 1999;37:457–470
  5. Oshika T . Ocular adverse effects of neuropsychiatric agents: incidence and management . Drug Saf . 1995;12:256–263

PII: S1726-4901(09)70335-1

doi: 10.1016/S1726-4901(09)70335-1

Journal of the Chinese Medical Association
Volume 69, Issue 12 , Pages 589-590 , December 2006

Article Tools